|
Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11e
3/1/2010: 2009 in Review: Synopsis of Noteworthy FDA Approvals
Nelda Murri
Chief of Pharmacy, Jonathan M. Wainwright Memorial VA Medical Center, Clinical Assistant Professor, UW School of Pharmacy
Topics Discussed: angioneurotic edema, hereditary; anti factor xa; anti-anxiety agents; antidepressive agents; anti-inflammatory agents, non-steroidal; antineoplastic agents; antipsychotic agents; artemether; atypical antipsychotic; benflumetol; botulinum toxins; c1 inhibitor antigen measurement; cervical cancer; colchicine; drug design and development; dysfibrinogenemia; epilepsies, partial; fibrinogen; genital warts; haemophilus influenzae; hematinics; human papilloma virus vaccine; immunosuppressive agents; influenza a virus, h1n1 subtype; japanese encephalitis vaccines; lipid-lowering therapy; malaria; monoclonal antibodies; neuromuscular blocking agents; ophthalmic drugs; pancrelipase; pharmacotherapy of dermatologic disorders; pharmacotherapy of immunologic disorders; pharmacotherapy of infectious diseases; progressive multifocal leukoencephalopathy; protein synthesis inhibitors; psoriasis; swine influenza; swine-origin influenza virus; therapy of microbial diseases; bacterial, viral, fungal, and protozoal infections; vaccines, toxoids, and other immunobiologics; vasopressins; vigabatrin.
Related to Chapter 17. Drug Therapy of Depression and Anxiety Disorders; Chapter 18. Pharmacotherapy of Psychosis and Mania; Chapter 26. Analgesic-Antipyretic and Antiinflammatory Agents; Pharmacotherapy of Gout; Chapter 29. Vasopressin and Other Agents Affecting the Renal Conservation of Water; Chapter 35. Drug Therapy for Hypercholesterolemia and Dyslipidemia; Chapter 36. Pharmacotherapy of Gastric Acidity, Peptic Ulcers, and Gastroesophageal Reflux Disease; Chapter 46. Protein Synthesis Inhibitors and Miscellaneous Antibacterial Agents; Chapter 51. Antineoplastic Agents; Chapter 52. Immunosuppressants, Tolerogens, and Immunostimulants; Chapter 53. Hematopoietic Agents: Growth Factors, Minerals, and Vitamins; Chapter 60. Insulin, Oral Hypoglycemic Agents, and the Pharmacology of the Endocrine Pancreas; Chapter 63. Ocular Pharmacology; Chapter 9. Agents Acting at the Neuromuscular Junction and Autonomic Ganglia; 1699;
Excerpt:
"The FDA approved 26 drugs of note in 2009. Most are pharmacologically similar to others already marketed in the United States (see Table I: New Names of Botulinum Toxins, Table II: Drugs Approved for New Purposes or as Novel Formulations in 2009, Table III: New Drugs Licensed in 2009 with Mechanisms Similar to Previously Approved Drugs). Among the remainder are 3 "first-of-a-kind" medicines on the U.S. market for malaria, hereditary angioedema, and psoriasis (see Table IV: New Pharmacological Drug Classes Introduced in 2009 and monographs below). ..."
|
|
|
|
|